Straits Times Index
3,269.06 +43.89 (+1.36%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,823.04 +311.35 (+1.89%) FTSE 100
8,058.27 +34.40 (+0.43%) Bitcoin USD
66,015.62 -75.53 (-0.11%) CMC Crypto 200
1,393.03 -21.73 (-1.54%)
Daré Bioscience, Inc. (DARE)
After hours:
| Previous close | 0.2800 |
| Open | 0.2802 |
| Bid | 0.2903 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 0.2800 - 0.2990 |
| 52-week range | 0.2700 - 1.1000 |
| Volume | |
| Avg. volume | 445,291 |
| Market cap | 29.702M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.67 |
GlobeNewswireDaré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from the postcoital test clinical study
Insider MonkeyDaré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript March 28, 2024 Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.12. DARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the conference call hosted […]
- Thomson Reuters StreetEvents
Q4 2023 Dare Bioscience Inc Earnings Call
Q4 2023 Dare Bioscience Inc Earnings Call
